OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been given an average rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $13.3889.

A number of analysts have weighed in on OPRX shares. Stifel Nicolaus increased their target price on OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. JMP Securities increased their target price on OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. UBS Group set a $23.00 target price on OptimizeRx in a research note on Friday, October 10th. Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a research note on Friday, October 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OptimizeRx in a research note on Wednesday, October 8th.

Insider Buying and Selling at OptimizeRx

In other news, Director Patrick D. Spangler sold 11,120 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the transaction, the director owned 44,215 shares in the company, valued at approximately $773,320.35. This trade represents a 20.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer owned 188,916 shares in the company, valued at approximately $3,542,175. This represents a 0.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors have recently made changes to their positions in the company. Whetstone Capital Advisors LLC increased its stake in shares of OptimizeRx by 11.7% during the first quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock valued at $13,062,000 after buying an additional 157,880 shares during the period. Blair William & Co. IL increased its stake in shares of OptimizeRx by 4.9% during the first quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock valued at $5,465,000 after buying an additional 29,648 shares during the period. Parkman Healthcare Partners LLC purchased a new position in shares of OptimizeRx during the first quarter valued at $4,114,000. Manatuck Hill Partners LLC grew its stake in OptimizeRx by 139.5% in the second quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after purchasing an additional 265,000 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in OptimizeRx in the first quarter valued at about $2,542,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Down 5.1%

Shares of OPRX opened at $19.44 on Thursday. The company has a market cap of $360.90 million, a PE ratio of -36.00 and a beta of 1.25. The business has a fifty day moving average of $18.85 and a 200 day moving average of $14.93. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $22.25. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.21.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.